A Randomized, Open-Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-493 and ABT-530 in Adult Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
Phase of Trial: Phase II
Latest Information Update: 03 Jul 2015
At a glance
- Drugs Glecaprevir (Primary) ; Pibrentasvir (Primary) ; Dasabuvir; Ombitasvir/paritaprevir/ritonavir; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors AbbVie
- 10 Jun 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov record.
- 23 Apr 2014 According to ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.
- 06 Mar 2014 According to ClinicalTrials.gov record, planned end date changed from 1 May 2015 to 1 Jun 2015.